1. Home
  2. IPHA vs ACOG Comparison

IPHA vs ACOG Comparison

Compare IPHA & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.46

Market Cap

131.4M

Sector

Health Care

ML Signal

HOLD

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

N/A

Current Price

$6.10

Market Cap

110.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
IPHA
ACOG
Founded
1999
2000
Country
France
Canada
Employees
163
57
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
131.4M
110.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IPHA
ACOG
Price
$1.46
$6.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
2
Target Price
$5.75
$16.00
AVG Volume (30 Days)
23.2K
38.5K
Earning Date
03-26-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$180.36
$139.22
Revenue Next Year
N/A
$134.48
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.18
$4.50
52 Week High
$2.63
$10.88

Technical Indicators

Market Signals
Indicator
IPHA
ACOG
Relative Strength Index (RSI) 50.44 46.61
Support Level $1.35 $5.00
Resistance Level $1.80 $6.59
Average True Range (ATR) 0.08 0.42
MACD -0.00 -0.07
Stochastic Oscillator 50.00 28.62

Price Performance

Historical Comparison
IPHA
ACOG

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Share on Social Networks: